Trial · NCT07906197
A Mass Balance Study on [14C]Levornidazole Disodium Phosphate for Injection in Healthy Chinese Adult Male Subjects
NCT07906197, Phase 1, Completed, Yangtze River Pharmaceutical Group Jiangsu Zilong Pharmaceutical Co. Ltd
3 sourcestrials-2026-11-12-0.5.0
Cite this record
ConductScience Library. A Mass Balance Study on [14C]Levornidazole Disodium Phosphate for Injection in Healthy Chinese Adult Male Subjects. Trials, record NCT07906197. Release trials-2026-11-12-0.5.0, 12 Nov 2026. https://conductscience.org/library/trials/NCT07906197
On this page
Trial
As registered on ClinicalTrials.gov, in the graph's capture of the registry.
- Title
- A Mass Balance Study on [14C]Levornidazole Disodium Phosphate for Injection in Healthy Chinese Adult Male Subjects
- NCT number
- NCT07906197
- Status
- Completed
- Phases
- Phase 1
- Enrollment
- 6 participants, actual
- Lead sponsor
- Yangtze River Pharmaceutical Group Jiangsu Zilong Pharmaceutical Co. Ltd
- Conditions
- Mass Balance Study
- Interventions
- Levornidazole Disodium Phosphate for Injection
- First posted
- 2026-10-30
- Last updated
- 2026-10-30
Source ClinicalTrials.gov
Registered outcomes11
Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.
| List | Outcome | Time frame | Description |
|---|---|---|---|
| Primary | Cumulative Percent Recovery of Total Radiocarbon (14C) | From Day 1 to Day 10 | Percentage recovery of total radioactivity (14C) in urine, feces, and exhale was determined based on total administered dose. |
| Primary | Percentage of Metabolite Detected in Plasma ，Urine, Feces | From Day 1 to Day 10 | The percentage of major metabolites detected in plasma urine, feces following \[14C\]levornidazole disodium phosphate single dose administration |
| Primary | Area Under the Plasma Concentration-time Curve From Time 0 to the Last Measurable Concentration (AUC0-t) of levornidazole | From Day 1 to Day 10 | AUClast is defined as the concentration of drug from time zero to the last observable concentration. |
| Primary | Area Under the Plasma Concentration-time Curve From Time 0 Extrapolated to Infinity (AUC0-∞) of levornidazole | From Day 1 to Day 10 | AUCinf is defined as the concentration of drug extrapolated to infinite time. |
| Primary | Maximum Observed Plasma Concentration (Cmax) of levornidazole | From Day 1 to Day 10 | Cmax is defined as the maximum concentration of drug. |
| Secondary | Clearance (CL) of levornidazole | From Day 1 to Day 10 | CL is defined as the clearance following administration of the drug. |
| Secondary | The Volume of Distribution (Vd) of levornidazole | From Day 1 to Day 10 | Vd is defined as the volume of distribution of the drug. |
| Secondary | Time of Maximum Observed Plasma Concentration (Tmax) of levornidazole | From Day 1 to Day 10 | Tmax is defined as the time (observed time point) of Cmax. |
| Secondary | Apparent Terminal Elimination Half-life (t1/2) of levornidazole | From Day 1 to Day 10 | |
| Secondary | Mean Residence Time (MRT0-t) of levornidazole | From Day 1 to Day 10 |
1 to 10 of 11Source ClinicalTrials.gov
See all 11 registered outcomesOutcomes0
Each outcome the trial posted results for, in ClinicalTrials.gov's words.
None in this release.
Results by group0
Each measurement the trial posted, group by group, in the words and numbers it posted.
None in this release.
Participant flow0
How many started, completed or left each group, period by period.
None in this release.
Adverse events0
Each adverse event the trial posted, group by group: the participants affected out of those at risk.
None in this release.
Adverse event totals0
The totals the trial posted for each group.
None in this release.
Papers0
The papers the trial lists on ClinicalTrials.gov.
None in this release.
Grants0
The grants NIH RePORTER links to the trial, newest funded first: NIH's, and some of AHRQ's, CDC's, FDA's and VA's. Each shows its title, principal investigators, organization and funder in its newest year.
None in this release.
Trial comparisons0
Comparisons of the trial's two groups, calculated by ConductScience from the counts it posted.
None in this release.
Tests0
The ConductCognition tests this trial's registered outcomes name, as ScienceGraph matched them in trial-tests-2026-11-12-0.2.1.
None in this release.
Data dates
The day each source was copied for this release.
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this trial from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/trials/v1/NCT07906197
GET https://conductscience.org/api/trials/v1/NCT07906197/registered